Detalhe da pesquisa
1.
The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis.
Diabetes Obes Metab
; 24(11): 2263-2272, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35801343